Business Wire

OCTASIC-INC

17.9.2020 04:02:10 CEST | Business Wire | Press release

Share
Panasonic and Octasic Extend sXGP Collaboration to 5G/Beyond 5G

Panasonic Corporation, a world-leading provider of diverse electronics technologies, B2B, communications and wireless solutions, and Octasic Inc., an innovation leader in low-power programmable processors for wireless and multimedia applications, today announced the enhancement of their ongoing collaboration to develop shared eXtended Global Platform (sXGP) solutions to include 5G and Beyond 5G based wireless network products, especially for mission-critical applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005982/en/

Panasonic and Octasic will combine resources and expertise to develop high-performance, high reliability, and low-latency Small Cell solutions for the cellular IoT space, applied to B2B, Non-Terrestrial Networks in Avionics and other mission-critical verticals based on Octasic's OCT3032 System-on-Chip.

The Collaboration on sXGP

Panasonic has developed an sXGP wireless base station that makes full use of the OCT3032's embedded Opus DSP technology and realizes stable communication even in environments with high interference in unlicensed bands.

The 5G Collaboration

The expanded collaboration addresses the challenging requirements of developing a new class of Small Cells to be deployed in a wireless base station platform that contributes to mission-critical applications for advanced IoT environments and non-terrestrial operations toward 5G and Beyond 5G.

Octasic’s programmable processor platform delivers on the low power requirements of Panasonic Small Cell designs and accelerates development and support of multiple air interfaces from sXGP to 3GPP. More importantly it addresses the need for deterministic air interface design to meet the challenges of implementing an ultra-reliable low-latency solution in diverse environments from private campus-wide networks, to machine or robotic communication in warehouses, to aircraft systems.

Panasonic promotes the development of Ultra-Reliable and Low-Latency Communications (URLLC) functions that comply with both 3GPP and Non-Terrestrial Network (NTN) technologies and provides Octasic with engineering expertise and resources. In addition, Panasonic will accelerate digital transformation for itself and its customers demonstrating various IoT-related applications inside and outside the company.

Hideo Ohara, Director of Panasonic Technology Department, emphasized, “We are leveraging Octasic’s OCT3032 System-on-Chip, development tools, and 4G/5G software to develop and deploy differentiated sXGP, 4G, and 5G Small Cell network products that deliver on our world-leading technical requirements for high performance, highly reliable, low latency, and low power Small Cell network products. We are delighted to advance the evolution of society with such unique systems that are the culmination of our years of technological collaboration with Octasic.”

Fabio Gambacorta, Global VP Business Development and Sales at Octasic emphasized, “Offering a world-leading System-on-Chip solution for Small Cell designs does not happen by chance; it is critical to partner with an innovative wireless network OEM like Panasonic. Octasic is proud to collaborate on not only the development of Panasonic’s first sXGP network products, but to expand this collaboration to encompass future solutions for 3GPP-compliant 4G and 5G networks, especially those requiring high reliability, low latency, and low power.”

For more information about the OCT3032 SoC and its evaluation and development platforms, please contact pr@octasic.com or visit www.octasic.com/product/oct3032w/ .

About Octasic Inc.

Founded in 1998 and headquartered in Canada, Octasic develops innovative programmable processors for mobile wireless markets such as proprietary 4G/5G-based networks. Octasic’s Opus-based processor technology, programming tools, software and reference code reduce costs, mitigate risk, accelerate time-to-market, and allow developers to focus engineering resources on their areas of differentiation. With 20 years of technology development in low-power programmable System-on-Chip solutions, Octasic products deliver a low-power, low-latency “5G Small Cell on a Chip” for both commercial and private networks. For more information, please visit http://www.octasic.com/ .

About Panasonic Corporation

Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .

For media inquiries, please contact Global Communications Department:

https://news.panasonic.com/global/contacts/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye